MedTrace Logo

The Effects of Sorafenib on Molecular Barrett's Esophagus Cancer

NCT00619242 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2014-03-12

Study results available
· View outcomes & findings →

Summary

To determine whether sorafenib is able to change pre-cancerous cells in a way that we believe is important in the progression of cancer.

Conditions

  • Esophageal Cancer

Interventions

DRUG

sorafenib

2 tablets with water by mouth twice a day for two weeks.

Sponsors & Collaborators

  • Bayer

    collaborator INDUSTRY

  • University of Chicago

    lead OTHER

Principal Investigators

  • Ezra Cohen, MD · University of Chicago

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-06-30
Primary Completion
2009-09-30
Completion
2009-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00619242 on ClinicalTrials.gov